Conquering the number one killer of Minnesotans is no easy task.
At the University of Minnesota Medical School, cancer research comes in all shapes and sizes.
From cancer prevention, to clinical trials and treatment, our strong tie with the University of Minnesota's National Cancer Institute-designated Masonic Cancer Center, allows research to transition from the lab to real-world use in record time.
Current research strengths include projects as wide-ranging as bone marrow transplant (BMT), sarcoma research, and breast cancer prevention and treatment.
Masonic Cancer Center researchers have:
- Developed a promising new drug for treating pancreatic cancer
- Created breathing lungs in University laboratories
- Identified a master regulator of a key cancer-causing gene responsible for up to 20 percent of cancers
- Made continuing inroads into understanding hematopoietic stem cells.
The University is also proud to call some of the world’s top pediatric cancer programs its own.
Conquering breast cancer
Douglas Yee, MD, director of the Masonic Cancer Center and John H. Kersey Chair in Cancer Research, is working to conquer breast cancer. Yee is the point person for cancer research at the University of Minnesota and a professor in the Department of Medicine at the Medical School. He also treats patients with breast cancer and researches experimental new therapies.
The focus of this research is to understand the contribution of insulin-like growth factor (IGF) action to the breast cancer malignant phenotype, and develop anti-IGF strategies with potential as cancer therapeutics.
Yee is co-chair of the Agent Selection Committee for I-SPY2, a national clinical drug trial the University is participating in for women who have large tumors and are receiving chemotherapy.
Efforts to combat breast cancer are also happening at the basic science level. Carol Lange, PhD, studies cancer cells under stress in her lab, in particular the negative effect of certain hormones.
Nicotine addiction and treatment
Dorothy Hatsukami, PhD, is a nationally renowned expert in the field of nicotine addiction and treatment. Hatsukami is the associate director for Cancer Prevention and Control in the Masonic Cancer Center and Forster Family Professor in Cancer Prevention in the Department of Psychiatry at the University of Minnesota Medical School. She directs tobacco research programs at the University, and is a past president of the Society of Research on Nicotine and Tobacco.
Hatsukami’s research focuses on developing methods and measures to evaluate tobacco products, and works to develop a baseline of scientific research informing legislation to reduce tobacco-caused death and disease.
Hatsukami has served on a variety of national committees including the FDA’s Tobacco Product Scientific Advisory Committee. Recent discoveries from Hatsukami and collaborators include:
Cancer research at the U
Over 500 members working in a collaborative research environment focused on the causes, prevention, detection, and treatment of cancer. Designated by the National Cancer Institute as one of only 41 comprehensive cancer centers in the country.
Educating medical students, physicians, adiation technologists, physicists, and the public regarding cancer prevention, treatment, research, and advocacy.
Committed to providing the highest quality care based on cutting edge research to patients with cancer or non-malignant hematologic diseases such as sickle cell disease. Dedicated to advancing research on the biological underpinnings of cancer, stem cell biology, sickle cell anemia, endothelial cell biology, and tumor immunology. Over 50 full-time academic investigators involved in interdisciplinary research and patient care are devoted to training the next generation of academic leaders.
The nation’s most prominent laboratory investigating angiogenesis in gynecologic malignancies and training Gynecologic Pathologists.
Dedicated to reducing cancer health disparities experienced by racial and ethnic minority populations in Minnesota with an initial focus on Minnesota’s growing new immigrant and refugee populations. To achieve this aim, we focus on cutting-edge research, community engagement and training with strong emphasis on Community-based Participatory Research.
- Avdulov S, Herrera J, Smith K, Peterson M, Gomez-Garcia JR, Beadnell TC, Schwertfeger KL, Benyumov A, Manivel JC, Li S, et al. 2015. EIF4E threshold levels differ in governing normal and neoplastic expansion of mammary stem and luminal progenitor cells. Cancer Research 75(4):687-697.
- Hui SK, Arentsen L, Wilcox A, Shanley R, Yee D, Ghebre R. 2015. Spatial and temporal fracture pattern in breast and gynecologic cancer survivors. Journal of Cancer 6(1):66-69.
- Hui SK, Arentsen L, Sueblinvong T, Brown K, Bolan P, Ghebre RG, Downs L, Shanley R, Hansen KE, Minenko AG, et al. 2015. A phase I feasibility study of multi-modality imaging assessing rapid expansion of marrow fat and decreased bone mineral density in cancer patients. Bone 73:90-97.
In the news
- Almost two decades later, doctor reflects on using embryo selection to save young girl’s life
- Research Snapshot: A detailed look at HTLV-1, the retrovirus that causes T-cell Leukemia
- Research Snapshot: Some melanoma survivors still practice unhealthy sun behaviors
- Should All Breast Cancer Patients Receive Adjuvant Chemotherapy Treatment?
- ACA repeal could greatly impact women’s health
Grants and awards
- Branden Moriarity, PhD, Pediatrics' Division of Pediatric Hematology/Oncology, has received a 2015 V Scholar Grant from the V Foundation for Cancer Research to fund "The Role and Therapeutic Targeting of PVT1 Mediated MYC Stabilization in Pediatric Sarcomas" (2015)
- Jeffrey Miller, MD, Medicine's Hematology, Oncology and Transplantation, named National Cancer Institute Outstanding Investigator Read more (2015)
- Reuben Harris, PhD, Biochemistry, Molecular Biology and Biophysics, was selected by the Howard Hughes Medical Institute (HHMI) as an HHMI Investigator (2015)
- Jeffrey Miller, MD, Medicine's Hematology, Oncology and Transplantation, receives a grant for the study of ALT-803 in Patients with Relapsed or Refractory Multiple Myeloma (2015)